Pediatrics’ Max Wiznitzer weighs new ADHD treatment option for patients who don’t respond to existing medications

FDA Approves ‘First-in-Class’ NDSRI for ADHD in Adults and Children

Healthline: Max Wiznitzer, pediatric neurology professor at the School of Medicine, said he welcomes the FDA approval of SIMTRIYO as another ADHD treatment option but noted he would initially reserve it for patients who don't respond to existing medications until more evidence shows it outperforms stimulant therapies.